Fulcrum Therapeutics, Inc. 8-K

What Happened Fulcrum Therapeutics, Inc. filed an 8‑K on June 25, 2026 reporting the results of its June 24, 2026 annual meeting. Stockholders elected three Class I directors — Sonja Banks, Alan Ezekowitz, and Colin Hill — each to a three‑year term ending in 2029. Shareholders also approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers, and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Directors elected (three‑year terms ending at the 2029 annual meeting):
  • Sonja Banks: 43,187,717 votes for; 10,601,385 withheld; 5,062,117 broker non‑votes.
  • Alan Ezekowitz: 52,317,282 votes for; 1,471,820 withheld; 5,062,117 broker non‑votes.
  • Colin Hill: 52,363,595 votes for; 1,425,507 withheld; 5,062,117 broker non‑votes.
• Advisory vote on named executive officer compensation (non‑binding): 50,735,617 for; 3,026,397 against; 27,088 abstain; 5,062,117 broker non‑votes.
• Ratification of Ernst & Young LLP as independent auditors for fiscal 2026: 58,793,645 for; 36,178 against; 21,396 abstain; 0 broker non‑votes.

Why It Matters These results confirm board continuity with three directors re‑elected and show substantial shareholder support for company leadership. The "say‑on‑pay" approval is advisory (non‑binding) but signals investor acceptance of executive compensation practices. Ratifying Ernst & Young maintains auditor continuity for Fulcrum’s financial reporting for fiscal 2026. Broker non‑votes on the director and advisory items (5,062,117 shares) reflect shares held by brokers that were not voted on non‑routine matters, which can affect vote majorities on those items.